The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid ...

Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is “the ...

Fueled by advances in biomarkers, brain mapping, and AI, investment in neuro and CNS innovation shows no signs of slowing, even amid costly setbacks. BioSpace spoke to investors at JPM26 to get their ...

In this episode of Denatured, BioSpace editorial team members, Senior Editor, Annalee Armstrong, and News Editor, Dan Samorodnitsky, discuss their post-JPM takeaways and 2026 forecasts after speaking ...

The U.S. regulator shared the roadmap for implementing the program, first proposed in August 2025, and teased changes made in response to industry feedback.

Looking for a research and development job? Check out the BioSpace list of 12 companies hiring life sciences professionals like you.

Competition for biotech and pharma employment picked up year over year and remains strong, according to BioSpace data. A survey late last year showed that 64% of employed/contract and 96% of ...

Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year.

After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will ...

Reporting Q4 and full year earnings on Wednesday, J&J executives hailed growth across the healthcare giant’s portfolio while ...

A renewal of the FDA’s pediatric rare disease voucher program is couched within a massive $1.2 trillion spending bill the ...

The star of the acquisition, anti-IgE antibody ozureprubart, is being tested as a prophylactic treatment for food allergies, ...